Abstract
Lenalidomide is an immunomodulatory drug approved in the United States for use with rituximab in patients with relapsed/refractory follicular lymphoma. We reviewed data from trials addressing the safety and efficacy of lenalidomide alone and in combination with rituximab as a first-line therapy and as a treatment of patients with relapsed/ refractory follicular lymphoma. Lenalidomide-rituximab has been demonstrated to be an effective chemotherapy-free therapy that improves upon single-agent rituximab and may become an alternative to chemoimmunotherapy.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 2133-2136 |
| Number of pages | 4 |
| Journal | Blood |
| Volume | 135 |
| Issue number | 24 |
| DOIs | |
| State | Published - Jun 11 2020 |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology